Clinical Trials Logo
  1. Home
  2. Optic Neuritis
  3. NCT01962571

Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial — TONE  

Optic Neuritis Clinical Trial

Official title:
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial

Clinical Trial Summary

This clinical trial aims at preventing visual dysfunction and optic nerve degeneration associated with autoimmune optic neuritis by systemic i.v. administration of 33.000 IU erythropoietin over 3 days. The primary objective is to determine the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone as assessed by measurements of retinal nerve fibre layer thickness and low contrast visual acuity 6 months after acute optic neuritis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01962571
Study type Interventional
Source University Eye Hospital, Freiburg
Contact
Status Completed
Phase Phase 3
Start date November 25, 2014
Completion date November 26, 2019
View Details
See also
  Status Clinical Trial Phase
Unknown status NCT00261326 - Simvastatin Treatment of Patients With Acute Optic Neuritis Phase 3
Recruiting NCT03963310 - Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
Recruiting NCT03586557 - Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis N/A
Recruiting NCT05487989 - VIsual Pathways Model in Neuro-inflammatory Disorders
Terminated NCT04131764 - Diagnosis of ON With or Without MS or NMOSD
Recruiting NCT03302585 - High-Dose Vitamin D Induction in Optic Neuritis Phase 2
Recruiting NCT02886377 - The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset N/A
Completed NCT01987167 - Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis Early Phase 1
Completed NCT01451593 - Neuroprotection With Phenytoin in Optic Neuritis Phase 2
Completed NCT03630497 - BN201 SAD MAD Study in Healthy Subjects Phase 1
Completed NCT01337986 - Ampyra for Optic Neuritis in Multiple Sclerosis Phase 2/Phase 3
Completed NCT01274702 - Visual Reconstitution Therapy After Optic Neuritis Phase 2
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Withdrawn NCT00037115 - Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Phase 4
Recruiting NCT04257734 - Epidemiologic and Clinical Characteristics of Optic Neuritis in China
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT02939937 - Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis Phase 2
Recruiting NCT04148781 - Fampridine-SR and Optic Neuritis Recovery Early Phase 1
Not yet recruiting NCT04289909 - Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) N/A
Completed NCT01524250 - Optic Neuritis Recovery After Oral or IV Corticosteroids Phase 2/Phase 3